UAB’s Director Of Infectious Diseases Warns Caution Around COVID-19 Vaccines In Trial

UAB's Facebook Page

The director of infectious diseases at the University of Alabama at Birmingham says right now she would not take one of the COVID-19 vaccines currently in phase three clinical trials across the country.

During a press conference Thursday, Dr. Jeanne Marrazzo addressed the Centers for Disease Control’s announcement that a vaccine could be ready by the end of October. She said the vaccines have been fast-tracked and not much is known about their long term effects or success rates.

“Yes, I know there’s urgency, but we should not sacrifice our convenience for the rush to get a product that we just don’t know is really truly safe,” Marrazzo said. “We deserve the best. We deserve better. I mean people have been through hell with this thing.”

Efficacy trials, or better known as phase three trials, help determine if a vaccine works. In the case of COVID-19, for a phase three trial to be successful it must show that the vaccine reduces the number of actual infections in people and that participants are able to make antibodies against the virus over time.

But now, Marrazzo said, those efficacy standards may change with the release of data from a vaccine trial in the United Kingdom earlier this week.

“My big concern about this timeline that’s now out there is that not only do we not have the kind of evidence for efficacy, yet. Yet. I’m saying yet because maybe they know something I don’t know. That’s always possible,” Marrazzo said. “But do we really have confidence that we can go out there and vaccinate everybody safely without knowing the longer-term benefits or side effects of this vaccine?”

Marrazzo said she is also concerned that there is not enough information yet about long-lasting immunity to COVID-19, especially given recent reports of people being reinfected with the virus. She noted that the vaccines are based on a totally new technology.

“We have never had a messenger RNA vaccine in a human population before these trials,” Marrazzo said. “We think it’s safe, but we don’t know.”

She added that vaccines can have serious side effects. Marrazzo said phase three trials typically follow participants for at least a year, if not longer, to track possible side effects. If a vaccine is released in late October, it would have only been studied in humans for eight months – at most.

“We need iron-clad proof and assurance to the extent that anybody can get it in any vaccine study or any medical study that whatever product we make widely available to our citizens is as safe and effective as humanly possible,” Marrazzo said. “We are not there, right now. There’s no way I have seen, myself, and I know that most experts have seen enough data to feel like not only today there’s something to roll out but in seven short weeks … that there would be something to roll out.”

Marrazzo said ultimately the decision to get the vaccine is a risk-benefit analysis, but she will not get one unless it is backed by the Advisory Committee on Immunization Practices. Meanwhile, Marrazzo said she plans on volunteering for a vaccine clinical trial.

Editor’s Note: UAB holds WBHM’s broadcast license, but our news and business departments operate independently.

UAB's Dr. Jeanne Marrazzo gives an update about COVID-19 as we head into Labor Day weekend.

Posted by WBHM on Thursday, September 3, 2020

More Coronavirus Coverage

Health Experts: Scale Back Thanksgiving Plans To Avoid COVID-19

Research from Georgia Tech University shows there is a one in five chance you will catch the virus if you gather with a group of ten people in Jefferson County.

Hospitalized For Months: One Man’s Fight Against COVID-19

COVID-19 has left 38-year-old Victor Perea hospitalized for almost three months. His wife wants others to understand how bad the virus can be.

Jones Pleads With Public To Follow COVID Safety Guidelines As Cases And Deaths Increase

Health experts are warning about gathering with friends and family over the upcoming Thanksgiving holiday.

Rising COVID-19 Cases Starting To Strain Hospital Resources, Staff

The COVID-19 caseloads in Alabama hospitals are "worsening fairly rapidly," according to the president of the Alabama Hospital Association.

Commission OKs Cares Act Funding In Quick Session

"We don’t want to send money back to Washington. We want to make sure that it’s spent here and for us to do that, we need to make sure we’ve looked at every avenue possible," said Jefferson County Commissioner Steve Ammons.

Birmingham Council Balks At Mayor’s Plan To Bring Back Some Workers, Wants More Information

Birmingham Mayor Randall Woodfin wants to use $7 million from the reserve fund to bring back more than 130 furloughed city employees. But the city council is not sold.

More Coronavirus Coverage